Lilly to buy Atai Beckley for USD 6.75 a share plus CVR up to USD 2.5 - ATAI News | RalliesLilly to buy Atai Beckley for USD 6.75 a share plus CVR up to USD 2.5
A
ATAI• Lilly agrees to acquire Atai Beckley in cash-and-CVR deal
- Lilly agreed to buy Atai Beckley for USD 6.75 a share in cash, valuing the equity at about USD 2.8 billion.
- The deal includes a contingent value right (CVR) worth up to USD 2.5 a share tied to development and U.S. approval milestones for BPL-003 and VLS-01.
- The transaction is expected to close in the third quarter, subject to Atai Beckley stockholder approval and other customary conditions.
- BPL-003 is an intranasal 5-MeO-DMT program for treatment-resistant depression; VLS-01 is a buccal DMT formulation in Phase 2b.
- The offer represents about a 40% premium to the 30-day volume-weighted average share price through July 15, 2026.
